AU2008201937B2 - Biosynthetic genes for butenyl-spinosyn insecticide production - Google Patents

Abstract

The present invention relates generally to butenyl-spinosyn biosynthetic genes, spinosyn producing microorganisms transformed with the biosynthetic genes, methods using the biosynthetic genes to increase production of butenyl-spinosyn insecticidal macrolides, and methods using the genes or fragments thereof to change the products produced by spinosyn-producing microorganisms.

Description

AUSTRALIA Patents Act COMPLETE SPECIFICATION (ORIGINAL) Class Int. Class Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority Related Art: Name of Applicant: Dow AgroSciences LLC Actual Inventor(s): Brian S. Bullard, Gary D. Gustafson, Donald R. Hahn, James D. Jackson, Jon C. Mitchell, Clive Waldron Address for Service and Correspondence: PHILLIPS ORMONDE & FITZPATRICK Patent and Trade Mark Attorneys 367 Collins Street Melbourne 3000 AUSTRALIA Invention Title: BIOSYNTHETIC GENES FOR BUTENYL-SPINOSYN INSECTICIDE PRODUCTION Our Ref: 828255 POF Code: 112152/112152 The following statement is a full description of this invention, including the best method of performing it known to applicant(s): -1 - 1A DESCRIPTION BIOSYNTHETIC GENES FOR BIJTENYL-SPINOSYN INSECTICIDE PRODUCTION The present application is a divisional application from Australian Patent Application No. 2002305 118, the entire disclosure of which is incorporated herein by reference. 5 Summary of the Invention 100011 The present invention provides novel butenyl-spinosyn biosynthetic genes, vectors incorporating the biosynthetic genes, Saccharopolyspora strains transformed with the biosynthetic genes, methods of using these genes to increase production of spinosyn-like insecticidal macrolides, and methods of using the genes or fragments thereof to change the 10 metabolites made by spinosyn-producing strains of Saccharopolyspora spp. Background of the Invention 10002] The naturally produced spinosyn compounds consist of a 5,6,5-tricylic ring system, fused to a 12-membered macrocyclic lactone, a neutral sugar (rhamnose) and an amino sugar (forosamine) (see Kirst et al., 1991). If the amino sugar is not present, the compounds 15 have been referred to as pseudoaglycones, and if the neutral sugar is not present then the compounds have been referred to as reverse pseudoaglycones. [00031 A83543 spinosyns are produced by Saccharopolyspora spinosa strain NRRL 18395 and derivatives thereof. The known members of the A83543 spinosyn family and the strains producing them have been disclosed in US Patent No. 5,362,634; 5,202,242; 20 5,840,861; 5,539,089 and 5,767,253. The compounds are identified by letter designation: spinosyn A, B, etc. (see Kirst et al., 1991). The structure of A83543 spinosyn A is given in Table 1 hereinafter. The A83543 spinosyn compounds are useful for the control of arachnids, nematodes and insects, in particular Lepidoptera and Diptera species, and they have favorable environmental and toxicological profiles. 25 [0004] DNA sequences for the genes encoding the enzymes which direct the biosynthesis of A83543 spinosyn are disclosed in U. S. Patent No. 6,143,526. The cloned genes and open reading frames are designated as spnA, spnB, spnC, spnD, spnE, spnF, spnG, spnH, spnl, spyz, spnK, spnL, spnM, sJN, snO, spnP. spnQ, spnR, spnS S. spinosa gtt, S. spinosa gdh, S. spinosa epi, and S. spinosa kre. 30 100051 The spinosyn biosynthetic genes, excluding those for rhamnose biosynthesis, specifically genes spnA, spnB, spnC, spnD, spnE, spnF, spnG, spnH, spnI, spn.J, spnK, spnL, spnM, spnN, spnO, spnP, spnQ, spnR, and spnS are located contiguously on an W3Files\70391T20023051 S-pIg1A doc WO 02/079477 PCT/US02/09968 -2 approximately 74 kb region of the S. spinosa chromosome. The spnA, spnB, spnC, spnD, and spnE genes were shown to be similar to genes responsible for polyketide biosynthesis and disruption of spnA, spnD, or spnE eliminated all spinosyn production. A83543 spinosyn synthesis also involves bridging of the lactone nucleus, an activity that is rare in macrolide producers; the spnF, spnJ, spnL, and spnM genes were believed to be involved in this biosynthetic step. The spnG, spnH, spn1, and spnK genes were reported to be involved in rhamnose addition and modification, and the spnN, spnO, spnP, spnQ, spnR and spnS genes were reported to be involved in biosynthesis and addition of the forosamine sugar. The genes required for rhamnose biosynthesis were not located contiguously to the rest of the A83543 spinosyn biosynthetic genes. S. spinosa gtt, and S. spinosa kre were cloned on a distinct fragment, and S. spinosa gdh and S. spinosa epi, were cloned on other distinct fragments. [0006] Recently a second class of spinosyns, the butenyl-spinosyns, produced by a novel organism, Saccharopolyspora sp. LW107129 (NRRL 30141) or derivatives thereof, was disclosed in US Appl. No. 09/661,065, corresponding to WO 01/19840, and in U.S. Patent Appl. No. 60/277,601. Over 40 members of this chemical family have been defined in the aforementioned applications. The butenyl-spinosyn compounds produced by Saccharopolyspora sp. LW107129 (NRRL 30141) are different from the compounds in the A83543 spinosyn series. The primary difference between the two classes of spinosyns is the substitution of the carbon tail attached to the macrocyclic ring at C-21. The natural butenyl spinosyns are substituted with a 3-4 carbon chain at C-21, preferably butenyl, while natural A83543 spinosyns are substituted with a 1-2 carbon chain at C-21, preferably ethyl. [0007] The butenyl-spinosyn compounds are useful as reactants in the production of synthetically modified spinosoid compounds as disclosed in the provisional U. S. Patent Application 60/277,546 on "Synthetic Derivatives of 21-Butenyl and Related Spinosyns," filed March 21, 2001. More preferably, the butenyl-spinosyn compounds and their synthetic derivatives are useful for the control of arachnids, nematodes and insects, in particular Lepidoptera and Diptera species. [0008] In addition to the butenyl group at C-21, butenyl-spinosyns exhibit a number of other differences from the A83543 spinosyn series. A subset of the butenyl-spinosyn compounds and factors which demonstrate diversity relative to A83543 spinosyns are -2- WO 02/079477 PCT/US02/09968 -3 summarized in Table 1. The butenyl spinosyns are named in Table I and referred to hereinafter by the structural acronyms "for-rham-I", "for-rham-II", "for-rham-HI' and derivatives thereof. In these cases I, II, and III refer to the appropriately-substituted macrolide structure (I: R 4

=R

5 =H; II: R! = CH 3 , R 4 = H or OH; III: R= H, R 4 = OH), 'for' represents the sugar at C-17 (for = forosamine), and 'rham' represents the sugar at C-9 (rham = tri-0-methylrhamnose). A second type of macrolide structure which is produced by strain NRRL 30141, with general Formula (2) having a 14-membered macrolide ring, is referred to hereinafter as IV and the fully glycosylated comound as "for-rham-IV". The butenyl-spinosyn compounds of formulae (1) and (2) are useful for the control of arachnids, nematodes and insects, in particular Lepidoptera and Diptera species, and they are quite environmentally friendly and have an appealing toxicological profile. [0009] These differences include extensive modifications at the C-21 position, hydroxylation at the C-8 position and substitution of alternate sugars, including neutral sugars, for forosamine at C-17. In addition, a compound possessing a 5,6,5-tricylic ring system, fused to a 14 membered macro-cyclic ring with forosamine and rhamnose attached at C-17 and C-9, respectively was previously disclosed in the aforementioned application. Table 1 R9, R9- 0 R3 o H O O H0 0, R3 R8O - R4 R8 O R4 o R5 O 5 (1) (2) cmpd. Name formula R R R R RR no. * ** 1 A83543 (1) (3a) H H ethyl (9a) spinosyn A 2 for-rham-I (1) (3a) H H 1-butenyl (9a) (butenyl spinosyn) 3 2"-hydroxy- for-rham-I (1) (3a) H H 1-butenyl (9d) 4 for-(3'-O-desmethyl (1) (3c) H H 1-butenyl (9a) rham)-I (3-ODM) 5 for-rham-II (1) (3a) H CH3 1-butenyl (9a) 6 for-rham-III (1) (3a) OH H 1-butenyl (9a) 7 24,25-dehydro-for- (1) (3a) H H 1,3-butadienyl (9a) rham-I -3- WO 02/079477 PCT/US02/09968 -4 cmpd. Name formnda R R 4 RW R' R no. * ** 8 ami-rham-I (1) (3a) H H 1-butenyl (9e) 9 3"-O-methyl-glu-rham- (1) (3a) H H 1-butenyl (9f) I -r a -I_() ( a O H-ue l9 10 ami-rham-Ill (1) (3a) OH H 1-butenyl (9e) I1I mole-rhamn-U (1) (3a) OH H 1-butenyl (9g) 12 24-demethyl-for-rham- (1) (3a) H H 1-propenyl (9a) 13 rham-I (1) (3a) H H 1-butenyl H 14 24-hydroxy-rham-I (1) (3a) H H 3-hydroxy-1- H butenyl 15 24-hydroxy- rham-m (1) (3a) OH H 3-hydroxy-1- H butenyl 16 22,23-dihydro-rham-I (1) (3a) H H n-butyl H 17 (4'-N-desmethyl-l",4"- (1) (3a) H H 1-butenyl (9h) diepi-for)-rham-I 18 5"-epifor-rham-I (1) (3a) H H 1-butenyl (9i) 19 24,25-dehydro-for- (1) (3a) OH H 1,3-butadienyl (9a) rham-III 20 24-desmethyl-for- (1) (3a) OH H 1-propenyl (9a) rham-M 21 for-rham-IV (2) (3a) H H ethyl (9a) 22 for-(4'-O-desmethyl- (1A) (3d) H H 1-butenyl (9a) rham) (4-ODM) 23 for-(3',4'-di-O- (lA) (3e) H H 1-butenyl (9a) desmethyl-rham)-I

*R

3 is a group having one of the following formulas (3a) through (3c) OMeMe OH Me OMeMe 0Oe Me M e Ve OH (3a) (3b) (3c) OMeMe OMeMe 0JCOH OH OMe OH (3d) (3e) **R9-is a group having one of the following formulas (9a) to (9i) -4- WO 02/079477 PCT/US02/09968 -. 5 H C H3C + a H 3 C (9a)

H

3 C H 3 C (9b) forosamine H H 3 C HO H C N HC1 3 HHC 9 H3C 2"hydroxyforosamihe Ha% HO HO H 2 C amicetose (9e) OH (90 3"-O-methylglucose C0 a3 HaC 490 HC HOC (9g) OH0 (h 0-methyloleandrose N CHa (9h) H'CHa

H

3 C H 4"-N-desmethy-1",4" N 'diepiforosamine

H

3 0 (91) 5"-epiforosamine [0010] Compounds 1-21 in Table I are produced by Saccharopolyspora sp. LW107129 (NRRL 30141) and are disclosed in U.S. Patent Application. 09/661,065, corresponding to WO 01/19840. Compounds 32 & 23 are disclosed in provisional U. S. Patent Application 60/277,601. on "Pesticidal Macrolides", filed March 21, 2001. [0011] Despite the differences between the structures of butenyl-spinosyns and A83543 spinosyns, it can be deduced that some of the biosynthetic genes would be similar. However, as detailed above, Saccharopolyspora sp. LW107129 (NRRL 30141) produces a wide range of unique butenyl-spinosyn factors and compounds, which have not been observed in the A83543 spinosyns. Therefore, this organism must also posses novel biosynthetic enzymes, which are distinct from the A83543 spinosyn biosynthetic enzymes of S. spinosa. Specifically, relative to A83543 spinosyns, Saccharopolyspora sp. LW107129 (NRRL 30141) butenyl-spinosyn biosynthetic enzymes must be capable of extending the polyketide chain by 2 carbons (resulting in butenyl rather than ethyl at C-21). -5- WO 02/079477 PCT/US02/09968 -6 They must also be able to synthesize and attach alternate amino and neutral sugars at C-17, and hydroxylate at C-8 & C-24. In addition, rhamnose methylation must be different in Saccharopolyspora sp. LW107129 (NRRL 30141) relative to S. spinosa. Blocked mutants of S. spinosa which exhibited altered methylation of the rhamnose on A83543 spinosyn (as disclosed in USP 5,202,242 and 5,840,861) typically produced mono-desmethylated rhamnose derivatives of A83543 spinosyns. Di-desmethyl rhamnose derivatives of A83543 spinosyns were only detected in the presence of methylase inhibitors like sinefungin. Mutants of Saccharopolyspora sp. LW107129 (NRRL 30141) with altered methylation of rhamnose produced di- and tri-desmethyl rhamnose derivatives of butenyl-spinosyns in high amounts, in the absence of methylase inhibitors. [0012] A challenge in producing butenyl-spinosyn compounds arises from the fact that a very large fermentation volume is required to produce a very small quantity of butenyl spinosyns. A cloned fragment of DNA containing one or multiple genes for butenyl spinosyn biosynthetic enzymes would enable duplication of genes to increase yield. A yield increase of this type was achieved in fermentation's of Streptomycesfradiae by duplicating the gene encoding a rate-limiting methyltransferase that converts macrocin to tylosin (Baltz et al., 1997) and in S. spinosa by duplicating the gtt & gdh genes (Baltz et al., 2000). [0013] Cloned butenyl-spinosyn biosynthetic genes also provide a method for producing new derivatives of the butenyl-spinosyns, with a different spectrum of insecticidal activity. Specific intermediates (or their natural derivatives) can be synthesized by mutant strains of Saccharopolyspora sp. LW107129 (NRRL 30141) in which certain genes encoding enzymes for butenyl-spinosyn biosynthesis have been disrupted using recombinant DNA methods. Such a strategy was used effectively to generate a strain of Saccharopolyspora erythraea producing novel 6-deoxyerythromycin derivatives (Weber & McAlpine, 1992). Also butenyl-spinosyn biosynthetic genes can be expressed in other organisms, such as S. spinosa, which produce similar compounds. When expressed from the native butenyl spinosyn promoter or a heterologous promoter these genes produce new hybrid molecules with some of the unique structural features of both spinosyns and butenyl-spinosyns. [0014] Novel intermediates can also be synthesized by mutant strains of Saccharopolyspora sp. LW107129 (NRRL 30141) orS. spinosa in which parts of certain genes encoding enzymes for butenyl-spinosyn biosynthesis have been replaced with parts of -6- WO 02/079477 PCTIUS02/09968 -7 the same gene which have been specifically mutated in vitro, or with corresponding parts of genes from other organisms. The hybrid gene will produce a protein with altered functions, either lacking an activity or performing a novel enzymatic transformation. A new chemical substance would accumulate upon fermentation of the mutant strain. Such a strategy was used to generate a strain of Saccharopolyspora erythraea producing a novel anhydroerythromycin derivative (Donadio et al., 1993). [0015] Biosynthesis of butenyl-spinosyns proceeds via stepwise condensation and modification of 2- and 3-carbon carboxylic acid precursors, generating a linear polyketide (Figure 1A) that is cyclized and bridged to produce the tetracyclic aglycone (Figure 1B). Pseudoaglycone (containing tri-O-methylated rhamnose) is formed next, then di-N methylated forosamine or an alternate sugar is added to complete the biosynthesis (Figure IB). Other macrolides, such as the antibiotic erythromycin, the antiparasitic avermectin and the immunosuppressant rapamycin, are synthesized in a similar fashion. In the bacteria producing these compounds, antibiotic biosynthesis is catalyzed by several very large, multifunctional proteins of a Type I polyketide synthase (PKS) (Donadio et al., 1991; Ikeda et al., 1999; Schwecke et al., 1995). Together the polypeptides form a complex consisting of an initiator module and several extender modules, each of which adds a specific acyl CoA precursor to a growing polyketide chain, and modifies the p-keto group in a specific manner (Figure 1A). The structure of a polyketide is, therefore determined by the composition and order of the modules in the PKS. A module comprises several domains, each of which performs a specific function. The initiator module consists of an acyl transferase (AT) domain for addition of the acyl group from the precursor to an acyl carrier protein (ACP) domain. The initiator module may also contain a KSQ domain, which is highly similar to p-ketosynthase (KS) domains, but an essential active site cysteine has been replaced by glutamine (Bisang, et al., 1999), so KSQ no longer has condensing activity. KSQ domains retain decarboxylase activity and determines the precursor specificity of the initiation module. The extender modules contain AT and ACP domains, along with an intact p-ketosynthase (KS) domain that adds the pre-existing polyketide chain to the new acyl-ACP by decarboxylative condensation. Additional domains may also be present in each extender modules to carry out specific p-keto modifications: a p-ketoreductase (KR) domain to reduce the p-keto group to a hydroxyl group, a dehydratase (DH) domain to -7- -8 remove the hydroxyl group and leave a double bond, and an enoyl reductase (ER) domain to reduce the double bond and leave a saturated carbon. The last extender module terminates with a thioesterase (TE) domain that liberates the polyketide from the PKS enzyme in the form of a macrocylic lactone. Polyketide synthase enzymes are generally encoded by 3-7 5 large open reading frames (Donadio et al., 1991; Ikeda et al., 1999; Schwecke et al., 1995). Assembly of a functional polyketide synthase requires specific protein-protein interactions between these proteins. [00161 Active macrolide antibiotics are derived from macrocyclic lactones by additional 10 modifications, such as methylation and changes in reductive state, and the addition of unusual sugars. Most of the genes required for these modifications, and for the synthesis and attachment of the sugars, are clustered around the PKS genes. The genes encoding deoxysugar biosynthetic enzymes are similar in producers of macrolide antibiotics, such as erythromycin and tylosin (Donadio et al., 1993; Merson-Davies & Cundliffe, 1994), and 15 producers of extracellular polysaccharides, such as the 0-antigens of Salmonella and Yersinia (Jiang et al., 1991; Trefzer et al., 1999). All these syntheses involve activation of glucose by the addition of a nucleotide diphosphate, followed by dehydration, reduction and/or epimerization. The resultant deoxy-sugar could undergo one or more additional modifications such as deoxygenation, transamination and methylation. The sugars are 20 incorporated into macrolides by the action of specific glycosyltransferases. Genes involved in the synthesis and attachment of a sugar may be tightly clustered - even transcribed as a single operon - or they may be dispersed (Ikeda et al., 1999; Shen et al., 2000; Aguirrezabalaga et al., 1998). 25 The discussion of the background to the invention herein is included to explain the context of the invention. This is not to be taken as an admission that any of the material referred to was published, known or part of the common general knowledge as at the priority date of any of the claims. 30 Throughout the description and claims of the specification the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers or steps. V:M-aNKJ NO DELETE0023051 1.do -8a [0017] The following terms are used herein as defined below: [0018] a.a. - amino acid. 5 [0019] AmR - the apramycin resistance-conferring gene. [0020] ACP - acyl carrier protein domain. [0021] AT - acyltransferase domain. 10 [0022] blocked mutant - mutant strain having a mutation blocking the function of a specific enzyme of a biosynthetic pathway such that a precursor or shunt product is produced. 15 20 25 30 Y:MaryWKI NO DELETE2002305S I .do WO 02/079477 PCT/US02/09968 -9 [0023] bp - base pairs. [0024] bus - butenyl-spinosyn biosynthetic gene. [0025] Butenyl-spinosyn - a fermentation product structurally distinct from A83543 spinosyns (Table 1), disclosed in US Appl. No. 09/661,065 and provisional U. S. Patent Apple. No. 60/277,60 1, or a similar macrocyclic lactone fermentation product produced by a microorganism utilizing all or most of the butenyl-spinosyn genes. [0026] Butenyl-spinosyn genes- the DNA sequences that encode the products required for butenyl-spinosyn biosynthesis, more specifically the genes busA, busB, busC, busD, busE, busF, busG, busH, busI, busJ, busK, busL, busM, busN, busO, busP, busQ, busR, and busS, as described hereinafter, or functional equivalents thereof. [0027] Cloning - the process of incorporating a segment of DNA into a recombinant DNA cloning vector and transforming a host cell with the recombinant DNA. [0028] Codon bias - the propensity to use a particular codon to specify a specific amino acid. In the case of Saccharopolyspora sp. LW107129 (NRRL 30141) , the propensity is to use a codon having cytosine or guanine as the third base. [00291 Complementation - the restoration of a mutant strain to its normal phenotype by a cloned gene. [0030] Conjugation - a process in which genetic material is transferred from one bacterial cell to another. [0031] cos - the cohesive end sequence of bacteriophage lambda. [0032] Cosmid - a recombinant DNA cloning vector which is a plasmid that not only can replicate in a host cell in the same manner as a plasmid but also can be packaged into phage heads. [0033] DH - dehydratase domain. [0034] ER - enoyl reductase domain. [0035] Gene - a DNA sequence that encodes a polypeptide. [00361 Genomic Library - a set of recombinant DNA cloning vectors into which segments of DNA, representing substantially all DNA sequences in a particular organism -9- WO 02/079477 PCT/US02/09968 -10 have been cloned. [0037] Homology - degree of similarity between sequences [00381 Hybridization - the process of annealing two single stranded DNA molecules to form a double stranded DNA molecule, which may or may not be completely base paired. [0039] In vitro packaging - the in vitro encapsulation of DNA in coat protein to produce a virus-like particle that can introduce DNA into a host cell by infection [0040] kb - kilo base pairs. [0041] KR - p-keto reductase domain. [0042] KS - ketosynthase domain. [0043] Mutagenesis - creation of changes in DNA sequence. They can be random or targeted, generated in vivo or in vitro. Mutations can be silent, or can result in changes in the amino acid sequence of the translation product which alter the properties of the protein and produce a mutant phenotype. [0044] ORF - open reading frame. [0045] ori - a plasmid origin of replication (oriR) or transfer (oriT). [0046] % Identity - the % identity value give by the BLAST program when two sequences are compared. [0047] % Similarity - the % similarity value given by the BLAST program when two sequences are compared. [0048] PCR - polymerase chain reaction - a method to specifically amplify a region of DNA. [0049] PKS - polyketide synthase. [0050] Promoter - a DNA sequence that directs the initiation of transcription. [0051] Recombinant DNA cloning vector - any autonomously replicating or integrating agent, including , but not limited to, plasmids, comprising a DNA molecule to which one or more additional DNA molecules can be or have been added. [0052] Recombinant DNA methodology - technologies used for the creation, -10- WO 02/079477 PCT/USO2/09968 -11 characterization, and modification of DNA segments cloned in recombinant DNA vectors. [0053] Restriction fragment - any linear DNA molecule generated by the action of one or more restriction enzymes. [0054] Spinosyn - a fermentation product also known as A83543, typically characterized by a 5,6,5-tricylic ring system, fused to a 12-membered macrocyclic lactone, with a 1-2 carbon chain at C-21, a neutral sugar (rhamnose) and an amino sugar (forosamine), or a similar macrocyclic lactone fermentation product produced by a microorganism utilizing all or most of the A83543 spinosyn genes. [00551 Spinosyn genes- the DNA sequences that encode the products required for A83543 spinosyn biosynthesis, more specifically the genes spnA, spnB, spnC, spnD, spnE, spnF, spnG, spnH, spn, spnJ, spnK, spnL, spnM, spnN, spnO, spnP, spnQ, spnR, spnS, S. spinosa gtt, S. spinosa gdh, S. spinosa epi, and S. spinosa kre, as described hereinafter, or functional equivalents thereof. [0056] spn - A83543 spinosyn biosynthetic gene. [00571 Subclone - a cloning vector with an insert DNA derived from another DNA of equal size or larger. [0058] TE - thioesterase domain. [00591 Transconjugant - recombinant strain derived from a conjugal mating. Brief Description of the Figures [0060] FIG.S 1A and 1B are a diagram illustrating the butenyl-spinosyn biosynthetic pathway. [00611 FIG. 2 is a map illustrating the arrangement of HindlII, EcoRV and ScaI fragments and open reading frames in the cloned region of Saccharopolyspora sp. LW107129 (NRRL 30141) DNA and location of butenyl-spinosyn genes on the cloned DNA. [0062] FIG. 3 is a restriction site and functional map of Cosmid pOJ436. [0063] FIG. 4 is a diagram illustrating the biosynthetic pathway for 17-(4"-0 methyloleandrose)-butenyl-spinosyn [Table 1; compound (11)]. -11- 12 Brief Description of the Invention [00641 Butenyl-spinosyn biosynthetic genes and related ORFs were cloned and the DNA sequence of each was determined. The cloned genes and ORFs are designated hereinafter as busA, busB, busC, busD, busE, busF, busG, busH, busl, busJ, busK, busL, busM, busN, busO, busP, busQ, busR, busS, ORF LI, ORF LII, ORF LIII, ORF LIV, ORF LVI, ORF LVII, ORF LVIII, ORF LIX, ORF RI, ORF RII and ORF RIII. The proposed functions of the cloned genes in spinosyn biosynthesis are identified FIG. 1 and in the discussion hereinafter. According to the present invention there is provided an isolated DNA molecule comprising a DNA sequence that encodes a butenyl-spinoxyn biosynthetic enzyme, wherein said enzyme is comprised of an amino acid sequence at least 98% identical to one selected from the group consisting of SEQ ID NOS 3-7, and 8-29, provided that if the sequence is less than 100% identical to the selected sequence, then the differences do not substantially affect the functional properties of the encoded enzyme. 100651 In one of its aspects, the invention provides an isolated DNA molecule comprising a DNA sequence that encodes a butenyl-spinosyn biosynthetic enzyme, wherein said enzyme is comprised of an amino acid sequence at least 98% identical to SEQ ID NO 3, provided that if the sequence is less than 100% identical to the selected sequence, then the differences do not substantially effect the functional properties of the encoded enzyme. [0065A In one of its aspects, the invention provides a process for preparing a butenyl spinosyn which comprises cultivating a microorganism having operative butenyl-spinosyn biosynthetic genes in its genome, provided that the genome of the organism has been modified so that duplicate copies of the butenyl-spinosyn biosynthetic gene busA is present. [00661 In another of its aspects, the invention provides an isolated DNA molecule comprising a DNA sequence that encodes a butenyl-spinosyn PKS domain selected from -12a KSi, ATi, ACPi, KSb, ATh, KRb, DHb, ACPb, KS1, ATI, KR1, and ACP1, said domains being described by, respectively, amino acids 6-423, 528-853, 895-977, 998-1413, 1495 1836, 1846-2028, 2306-2518, 2621--2710, 2735-3160, 3241-3604, 3907-4086, and 4181 4262 of SEQ ID NO:3. In a preferred embodiment, the DNA sequence is selected from the 5 group consisting of bases 16-1269, 1582-2559, 2683-2931, 2992-4239, 4483-5508, 5538 6084, 6916-7554, 7861-8130, 8203-9480, 9721-10812, 11719-12258, and 12541-12786 of 10 15 20 25 30 YAMarN)I NO DFIrrForm iniIn &..

WO 02/079477 PCT/US02/09968 -13 SEQ ID NO:1. [0067] In another of its aspects, the invention provides an isolated DNA molecule comprising a DNA sequence that encodes a spinosyn PKS domain selected from KS2, AT2, DH2, ER2, KR2, and ACP2, said domains being described by, respectively, amino acids 1 421, 534-964, 990-1075, 1336-1681, 1685-1864, and 1953-2031 of SEQ ID NO:4. In a preferred embodiment the DNA sequence is selected from the group consisting of bases 13059-14321, 14658-15900, 16026-16283, 17064-18100, 18111-18650, and 18915-19151 of SEQ ID NO:1. [0068] In another of its aspects, the invention provides an isolated DNA molecule comprising a DNA sequence that encodes a spinosyn PKS domain selected from KS3, AT3, KR3, ACP3, KS4, AT4, KR4, and ACP4, said domains being described by, respectively, amino acids 1-421, 528-814, 1157-1335, 1422-1503, 1526-1949, 2063-2393, 2697-2877, and 2969-3049 of SEQ ID NO:5. In a preferred embodiment the DNA sequence is selected from the group consisting of bases 19553-20815, 21143-22000, 23021-23557, 23816 24061, 24128-25399, 25739-26731, 27641-28183, and 28457-28699 of SEQ ID NO:1. [00691 In another of its aspects the invention provides an isolated DNA molecule comprising a DNA sequence that encodes a spinosyn PKS domain selected from KS5, AT5, DH5, KR5, ACP5, KS6, AT6, KR6, ACP6, KS7, AT7, KR7, and ACP7, said domains being described by, respectively, amino acids 1-422, 537-864, 891-1076, 1382-1563, 1643 1724, 1746-2170, 2281-2611, 2914-3093, 3186-3267, 3289-3711, 3823-4151, 4342-4636, and 4723-4804 of SEQ ID NO:6. In a preferred embodiment the DNA sequence is selected from the group consisting of bases 29092-30357, 30700-31683, 31762-32319, 33235 33780, 34018-34263, 34327-35601, 35932-36924, 37831-38370, 38647-38892, 38956 40224, 40560-41544, 42115-42999 and 43258-43503 of SEQ ID NO:1. [0070] In another of its aspects, the invention provides an isolated DNA molecule comprising a DNA sequence that encodes a spinosyn PKS domain selected from KS8, AT8, DH8, KR8, ACP8, KS9, AT9, DH9, KR9, ACP9, KS10, AT1O, DH10, KR1O, ACP10, and TE1O, said domains being described by, respectively, amino acids 1-424, 530-848, 885 1072, 1371-1554, 1650-1728, 1751-2175, 2289-2616, 2642-2775, 3131-3315, 3396-3474, 3508-3921, 4036-4366, 4389-4569, 4876-5054, 5148-5229, and 5278-5531 of SEQ ID -13- -14 NO:7. In a preferred embodiment, the DNA sequence is selected from the group consisting of bases 43945-45216, 45532-46488, 46597-47160, 48055-48606, 48892-49083, 49195 50469, 50S09-51792, 51868-52269, 53335-53889, 54130-54366, 54466-55707, 56050 57042, 57109-57651, 58570-59106, 59386-59631, and 59776-60537 of SEQ ID NO: 1. [0071) In another of its aspects the invention provides an isolated DNAmolecule comprising a DNA sequence that encodes a spinosyn PKS module, said module being selected from the group consisting of amino acids 6-977 of SEQ ID NO:3, 998-2710 of SEQ ID NO:3, 2735-4262 of SEQ ID NO:3, 1-2031 of SEQ ID NO:4, 1-1503 of SEQ ID NO:5, 1526-3049 of SEQ ID NO:5, 1-1724 of SEQ ID NO:6, 1746-3267 of SEQ ID NO:6, 3289 4804 of SEQ ID NO:6, 1-1728 of SEQ ID NO:7, 1751-3474 of SEQ ID NO:7, and 3508 5531 of SEQ ID NO:7. In a preferred embodiment the DNA sequence is selected from the group consisting of bases 16-2931, 2992-8130, 8203-12786, 13059-19151, 19553-24061, 24128-28699, 29092-34263, 34327-38892, 38956-43503, 43945-49083, 49195-54366, and 54466-60537 of SEQ ID NO:1. [0072] In another of its aspects, the invention provides a recombinant DNA vector which comprises a DNA sequence of the invention as described above. [0073] In another of its aspects the invention provides a host cell transformed with a recombinant vector of the invention as described above. [0074] In another of its aspects, the invention provides a method of increasing the spinosyn-producing ability of a spinosyn-producing microorganism comprising the steps of 1) transforming with a recombinant DNA vector or portion thereof a microorganism that produces butenyl-spinosyn or a butenyl-spinosyn precursor by means of a biosynthetic pathway, said vector or portion thereof comprising a DNA sequence of the invention, as described above, that codes for the expression of an activity that is rate limiting in said pathway, and 2) culturing said microorganism transformed with said vector under conditions suitable for cell growth and division, expression of said DNA sequence, and production of spinosyn.

-14a According to another aspect of the invention there is provided a process for preparing a butenyl-spinosyn which comprises cultivating a microorganism having operative butenyl-spinosyn biosynthetic genes in its genome, provided that the genome of the organism has been modified so that duplicate copies of at least one of the butenyl-spinosyn 5 biosynthetic genes busA, busB, busC, busD, busE, busF, busG, busH, busI, busJ, busK, busL, busM, busN, busO, busP, busQ, busR, and busS has are present. [0075] In another of its aspects the invention provides a spinosyn-producing microorganism having operative buienyl-spinosyn biosynthetic genes wherein at least one 10 15 20 25 30 WO 02/079477 PCT/US02/09968 -15 of the butenyl-spinosyn biosynthetic genes busA, busB, busC, busD, busE, busF, busG, busH, busI, busJ, busK, busL, busM, busN, busO, busP, busQ, busR, and busS has been duplicated. [0076] In another of its aspects the invention provides a butenyl-spinosyn-producing microorganism, said microorganism having butenyl-spinosyn biosynthetic genes in its genome, wherein at least one of said genes has been inactivated, the rest of said genes being operational to produce a butenyl-spinosyn other than the one that would be produced if the disrupted gene were operational. Preferably the microorganism is an Saccharopolyspora sp. LW107129 (NRRL 30141) or S. spinosa mutant More preferably the microorganism is an Saccharopolyspora sp. LW107129 (NRRL 30141) mutant [0077] The invention also provides for expression of butenyl-spinosyn biosynthetic genes in an organism which does not normally produce butenyl-spinosyns. The genes may be expressed under natural bus gene promoters or from a heterologous promoter compatible with the recipient strain. Preferably the organism is capable of producing spinosyn-like compounds. More preferably the microorganism is S. spinosa or a derivative thereof. [00781 The invention also provides a butenyl-spinosyn-producing microorganism having operational butenyl-spinosyn biosynthetic genes in its genome, wherein said genes a) include at least one operational PKS module more than or at least one less than is present in SEQ ID NO: 1; or b) include a PKS module that differs from the corresponding module described in SEQ ID NO: I by the deletion, inactivation, or addition of a KR, DH or ER domain, or by the substitution of an AT domain. Preferably the microorganism is an Saccharopolyspora sp. LW107129 (NRRL 30141) mutant [0079] The invention also provides butenyl-spinosyns produced by cultivation of the novel microorganisms of the invention. [00801 In another of its aspects the invention provides a process for isolating butenyl spinosyn biosynthetic genes which comprises creating a genomic library of a butenyl spinosyn producing microorganism, and using a labeled fragment of SEQ ID NO:1 or SEQ ID NO. 2 that is at least 20 bases long as a hybridization probe. [0081] It will be understood by those skilled in the art that substitutions can be made in the claimed amino acid sequences without substantially changing the functionality of the -15- -16 proteins. The invention encompasses such variant amino acid sequences and DNA sequences encoding the variants. Preferred amino acid sequences are those that have substantially the same functionality and are at least 98% identical to the native amino acid sequence. 5 According to another aspect of the invention there is provided a process for preparing a butenyl-spinosyn which comprises cultivating a microorganism having butenyl-spinosyn biosynthetic genes in its genome, provided that at least one of said genes has been inactivated, the rest of said genes being operational to produce a butenyl-spinosyn other than 10 the one that would be produced if the disrupted gene were operational. According to a further aspect of the invention there is provided a process for preparing a butenyl spinosyn which comprises cultivating a heterologous microorganism that has been transformed so that its genome contains operative butenyl spinosyn 15 biosynthetic genes. According to a still further aspect of the invention there is provided a process for preparing a butenyl spinosyn which comprises cultivating a microorganism having operational butenyl-spinosyn biosynthetic genes in its genome, wherein said genes a) 20 include at least one operational PKS module more than or at least one less than is present in SEQ ID NO: 1; or b) include a PKS module that differs from the corresponding module described in SEQ ID NO:1 by the deletion, inactivation, or addition of a KR, DH or ER domain, or by the substitution of an AT domain. 25 30 Y:MarfNKJ NO DELETE20023051 I3doc -16a Detailed Description of the Invention [0082] As a prerequisite for the characterization and utilization of butenyl-spinosyn genes, it is necessary to isolate and characterize the genes that encode the enzymes involved in the biosynthesis of this insect control agent. The approach described in the following 5 Example involves the construction of a genomic cosmid library Exaple inolvs te cnstucton f agenmiccosid ibrryand subsequent screening via DNA-hybridization. EXAMPLE 1 a. Isolation of total cellular DNA from Saccharopolvspora sm. LW107129 (NRRL 30141) 10 [00831 Saccharopolyspora sp. LW107129 (NRRL 30141) was inoculated into 100-mL vegetative media (9.0 g/L dextrose, 30 g/L trypticase soy broth, 3.0 g/L yeast extract, 2.0 g/L magnesium sulfate-7 H0) in a 500-mL Erlenmeyer flask and incubated shaking at 150 rpm for 72 hours at 30"C. This culture was centrifuged for 10 min. at 3,000 rpm/4"C to pellet the cells. The supernatant fluid was removed-and the cell pellet was washed with 20 15 mL of TE buffer (10 mM Tris/HCl pH 8.0; 1 mM EDTA pH 8.0). Cells were centrifuged again at 3,000 rpm and the pellet frozen at -20"C until it was thawed for total cellular DNA isolation. [0084]. Total cellular DNA was isolated from Saccharopolyspora sp. LWI07129 (NRRL 30141) (NRRL30141) using a Genomic DNA purification kit (Qiagen Inc., Valencia, CA). 20 Frozen bacterial cell pellets from 10) mL of culture were resuspended in 11 ml of Buffer BI (50 mM Tris/HCl, pH 8.0; 50 mM EDTA, pH 8.0; 0.5% Tween 20, 0.5% Triton X-100) containing 11 p.

1 of Qiagen Rnase A solution (100 mg/ml) by vortexing. To this suspension, 300 pl of a lysozyme (100 mg/ml; Sigma Chemical Co., St. Louis, MO) stock solution and 25 500 p1 of a proteinase K (50 mg/ml; Sigma Chemical Co.) stock solution was added. The suspension was mixed by vortexing and incubated at 37"C for 30 min. Four ml of Buffer B2 (3 M guanidine HCI; 20% Tween 20) was added to the bacterial lysates and mixed into solution by gentle inversion of the tubes. The bacterial lysates were incubated at 50"C for 30 min. Total cellular DNA was isolated from the bacterial lysates using Qiagen Genomic-tip 30 Y:\M.yWK NO DELETE20023051 It do WO 02/079477 PCT/US02/09968 -17 500/G tips as per manufacturer's instructions. The resulting purified DNA was dissolved in 5 mL TE buffer and stored at 4*C. b. Construction of genomic cosmid libry [0085] Total cellular DNA isolated from Saccharopolyspora sp. LW107129 (NRRL 30141) was partially digested with Sau3A I based on section 3.1.3 of Ausubel, et al. (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., New York, NY). Small-scale (40 pg of total cellular DNA in an 80 pl reaction volume) reactions were performed to determine the proper enzyme to total cellular DNA ratio that resulted in the maximal concentration of partially-digested DNA fragments in the 25-50 Kb size range. Reactions were heated at 65*C for 15 min to inactivate the Sau3A I enzyme and aliquots of the reactions were analyzed by electrophoresis in 0.3% agarose gels to determine the relative abundance of partially-digested DNA fragments in the desired size range. Once an optimal enzyme to total cellular DNA ratio was observed, the reaction volume was increased to obtain sufficient quantities of partially-digested total cellular DNA for use as insert DNA in the construction of the cosmid libraries. A typical scaled reaction was 400 sg of Saccharopolyspora sp. LW107129 (NRRL 30141) total cellular DNA incubated with 9 units of Sau3A I (Gibco BRL, Gaithersburg, MD) for 15 min at 37*C in 800 pl total volume of IX React 4 Buffer (supplied as lOX by the manufacturer). The reaction was heated at 65*C for 20 min to inactivate the enzyme. The partially-digested genomic DNA was mixed with an equal volume of an equilibrated phenol-chloroform (50:50; v/v) solution and mixed by gentle inversion. After centrifugation at 14,000 x g for 15 min, the aqueous phase was removed and mixed with an equal volume of a chloroform-isoamyl alcohol (24:1; v/v) solution. After mixing the two phases by gentle inversion, the solution was centrifuged at 14,000 x g for 15 min. The aqueous phase was removed to a fresh tube and 0.1 volume of 3 M sodium acetate (pH 5.2) was added. Two volumes of ice-cold 100% ethanol were added and the solution was mixed by inversion. To aid in the precipitation of the DNA, the samples were placed at -70*C overnight. The precipitated DNA was pelted by centrifugation at 14,000 x g for 20 min. The DNA pellet was resuspended in 50 pl double-distilled water and stored at -20"C. [0086] The vector used for construction of the cosmid library was pOJ436 (Figure 3) containing the apramycin resistance gene for selection. To minimize the re-ligation of -17- WO 02/079477 PCT/US02/09968 -18 cosmid vector DNA to itself, BamH I-digested pOJ436 DNA was dephosphorylated by incubating the digested DNA with 20 units of shrimp alkaline phosphatase (Roche/Boehringer Mannheim, Indianapolis, IN) for 2 hrs at 37"C in 1.2 ml total volume of 1X SAP buffer (supplied as 1oX by the manufacturer). Sau3A I-digested genomic DNA was ligated into the dephosphorylated BamH I site of pOJ436 and using a 5:1 ratio of partially-digested insert to vector DNA. For this reaction, insert and vector DNAs were incubated with 20 units of T4 DNA Ligase (New England BioLabs Inc., Beverly, MA) overnight at 16*C in 1X T4 DNA Ligase Buffer (supplied as 1OX by manufacturer). Ligation mixtures were packaged using Gigapack III Gold Packaging Extract (Stratagene, La Jolla, CA) and recombinant phage were titered using Escherichia coli strain DH5a MRC* cells (Gibco BRL), as described by the manufacturer's instructions. Aliquots (20-40 j1l) of the recombinant phage and host cell culture were spread onto LB agar (10 g/l Bacto tryptone, 10 g/l NaCi, 5 g/l Bacto-yeast extract, 15g/l Bacto agar; Difco Laboratories) containing apramycin (100mg/l; Sigma Chemical Co.) and incubated overnight at 37*C. To construct master plates of the cosmid libraries for freezer storage, single colonies were picked with sterile toothpicks and inoculated into individual wells of sterile 96-well microwell plates containing 250 jsl of Terrific Broth (TB media: 12 g/l Bacto-tryptone, 24 g/l Bacto-yeast extract, 0.4% v/v glycerol, 17 mM KH 2

PO

4 , 72 mM K 2

IPO

4 ) supplemented with 100mg/i apramycin and incubated without shaking overnight at 37"C. To generate copy plates from the master plates, a 96-well microplate replicator (V & P Scientific, Inc., San Diego, CA) was used to inoculate a sterile 96-well microwell plate containing 250 pl of TB media containing 100mg/l apramycin. Copy plates are incubated without shaking at 37"C overnight. [0087] For both master and copy plates, a 7 % (v/v) dimethylsulfoxide solution was added to the plates and the cultures and mixed using a multichannel pipette. Plates were placed at -70"C for storage. [00881 The average insert size of selected recombinant cosmids was assessed by isolating cosmid DNA using the NucleoSpin Nucleic Acid Purification Kit (CLONTECH Laboratories, Inc., Palo Alto, CA) and digesting the recovered DNA with 20 units of the restriction enzyme Eco RI (New England BioLabs) for 1 hr at 37"C. Restricted DNA was analyzed by electrophoresis in a 1.0% agarose gel. DNA fragments were visualized with -18- WO 02/079477 PCT/US02/09968 -19 UV light following 0.5% ethidium bromide (Sigma Chemical Co.) staining and relative size of fragments were estimated by comparison with 1 Kb DNA ladder (Gibco BRL). Insert size of the cosmid libraries constructed ranged from 20 Kb-40 Kb. c. Screening of cosmid libraries and identification of cosmids containing butenyl-spinosyn biosynthetic gene s [0089] Representatives of each E. coli cosmid clone were inoculated using a 96-well microplate replicator (V & P Scientific, Inc.) in duplicate onto Hybond N+ (Amersham Pharmacia Biotech, Piscataway, NJ) nucleic acid binding membranes. Membranes were supported on LB agar plates supplemented with 100 mg/L apramycin and incubated overnight at 37"C. Membranes were processed according the manufacturers' protocols. Inoculated membranes were placed colony-side up onto 3MM-filter paper (Whatman, Clifton, NJ) saturated with 0.5 N NaOH for 1 minute. Filters were transferred to 3MM filter paper saturated with 1 M Tris-HCl, pH 7.6 for 1 minute to denature the DNA. Membranes were neutralized by transfer to 3 MM-filter paper saturated with 1 M Tris-HCl, pH 7.6/1.5 M NaCl for 1 minute. Final washing was performed in a solution of 1 M Tris HCl, pH 7.6/1.5 M NaCl where remaining colony debris was removed from the membranes. DNA was cross-linked to the membrane with 1200 gjoules using an UV Stratalinker 1800 (Stratagene). [0090] The library of recombinant bacteria thus prepared was screened for homology to any of three radiolabelled DNA probes based upon the spn genes from S. spinosa (Baltz et al., 2000; Table 2). Pairs of oligonucleotides were used to amplify nucleotide regions specific for the spn biosynthetic gene cluster through polymerase chain reactions (PCR). Oligonucleotide primers were synthesized using a 394 DNA/RNA synthesizer (Applied Biosystems/PerkinElmer, Foster City, CA) and are listed in Table 2. PCR reactions were performed using AmpliTaq@ DNA Polymerase Kit (Perkin Elmer/Roche, Branchburg, NJ) according to manufacturer's protocols. DNA fragments were amplified in a 48-sample DNA Thermal Cycler (Perkin Elmer Cetus) under the following cycle conditions: 1) 94"C, 1 min.; 55"C, 2 min.; 72"C, 3 min.; 25 cycles 2) 72*C, 10 min.; 1 cycle. Amplified products were analyzed using 0.1% agarose gel electrophoresis and bands corresponding to the appropriate size were gel-extracted utilizing Qiagen II Gel Extraction Kit (Qiagen Inc.) as outlined according to manufacturer's directions. -19- WO 02/079477 PCT/US02/09968 -20 Table 2 S. spinosa Length Forward primer Reverse primer gene probe of probe (bp) spn S 499 SEQ ID NO. 33 SEQ ID NO. 34 spnF 536 SEQ ID NO. 35 SEQ ID NO. 36 spnE (TE) 506 SEQ ID NO. 37 SEQ ID NO. 38 [0091] Membranes were incubated at 65"C for 3 hours prior to addition of radiolabeled probe in 300 mls of pre-hybridization solution consisting of 6X SSC (52.59 g/L NaCl, 24.66 g/L sodium citrate, pH adjusted to 7.0 with 10 N NaOH), 0.1% sodium dodecyl sulfate (SDS), 1oX Denhardt's Solution (50 mg/L Ficoll [Type 400, Phannacia], 5.0 mg/L polyvinylpyrrolidone, 5.0 mg/L bovine serum albumin), 100 pg/ml denatured salmon sperm. [0092] Concentration of DNA fragments was adjusted to 25 ng for all probes, denatured for 10 minutes in a boiling water bath and random-prime labeled with 50 Ci [ac 3 P]dCTP, 3000 Ci/mMol using 4 ptl High Prime reaction mixture (Boehringer Mannheim) according to manufacturer's protocol. Separation of unincorporated nucleotides from radiolabeled DNA probes was performed using NucTrap Push Columns (Stratagene) and denatured for 10 minutes in a boiling water bath prior to addition to pre-hybridizing membranes. Approximately 2.0 x 10C cpm were added to membranes for all DNA hybridizations. Hybridization conditions for all probes were for 16 hours in shaking water 65*C bath. [0093] Hybridization solutions containing radiolabeled probes spnF, spnS, and spnE (TE) were decanted and each set of membranes washed under medium stringency conditions: 1) 15 min., room temperature in 300 ml 3X SSC/0.5 % SDS; 2) 30 min., 65 0 C shaking in 300 ml fresh 3X SSC/0.5 % SDS; 3) 30 min., room temperature in 300 ml 1X SSC/0.5 % SDS. Membranes screened with the radiolabeled probe derived from Saccharopolyspora sp. LW107129 (NRRL 30141) cosmid 9D3 sequence were washed under stringent conditions: 1) 30 min., 65"C shaking in 300 ml fresh 1X SSC/0.5 % SDS; 2) 30 min., 65"C shaking in 300 ml fresh 0.33X SSC/0.5 % SDS; 3) 30 min., 65*C shaking in 300 ml fresh 0. 1X SSC/0.5 % SDS. Filters were monitored using a hand-held Geiger Mueller counter to determine if background isotope detection was minimal. Membranes were mounted onto 3MM filter paper and covered with plastic wrap and exposed to x-ray -20- WO 02/079477 PCT/US02109968 -21 film. Membranes were allowed to expose film for 24-72 hours at -70*C prior to development. [0094] Putative positive cosmid clones were further characterized via restriction endonuclease digestion analysis and end-sequencing from the cosmid vector. Cosmid DNA was isolated using the NucleoSpin Nucleic Acid Purification Kit (CLONTECH Laboratories, Inc., Palo Alto, CA), and digested with 20 units of the restriction enzyme Eco RI (New England BioLabs) for 1 hr at 37"C. Restricted DNA was electrophoresed in a 1.0% agarose gel. DNA fragments were visualized with UV light following 0.5% ethidium bromide staining and relative size of fragments were estimated by comparison with 1 Kb DNA ladder. Additionally, Saccharopolyspora sp. LW107129 (NRRL 30141) nucleotide sequence from the cosmid/vector junctions was obtained by fluorescent cycle sequencing according to the methods of Burgett and Rosteck (1994). Sequencing reactions consisted of 3 pl (2 pg purified cosmid DNA) template, 141 universal primer (4 pmole) or reverse primer (4 pmole), 8 pl Big Dye@ reaction mixture, 1 ptl DMSO, 7 ml H 2 0 under thermal cycler conditions: 96*C, 30 sec.; 50*C, 15 sec.; 60*C, 4 min.; 25 cycles with a 377 ABI PrismTM Sequencer (Applied Biosystems, Inc.). [0095] Eight cosmid clones were identified as positively hybridizing to S. spinosa probes spnS, spnF and spnE (TE). Cosmid 8H3 was one of two clones that hybridized to both the spnS and spnF probes. Cosmid 9D3 was one of three clones that hybridized only to the spnF probe. Cosmid 1OC1 was one of three clones that hybridized only to the spnE (TE) probe. Cosmid 9F4 was identified from the genomic library by hybidization to a radiolabeled PCR-fragment derived directly from Saccharopolyspora sp. LW107129 (NRRL 30141) sequence elucidated through nucleotide sequencing of the cosmid/vector ends from cosmid 9D3 (bases 297477-30163 in SEQ ID NO: 1). Two primers were synthesized based on the cosmid 9D3 DNA sequence (SEQ ID NO:39 & SEQ ID NO:40). A 416 bp DNA fragment was amplified from Saccharopolyspora sp. LW107129 (NRRL 30141) genomic DNA using these primes as detailed above and used for hybridization. [0096] The complete sequences of cosmids 8H3, 9D3, 9F4 and 1OC1 were determined by the method of fluorescent cycle sequencing of random DNA fragments cloned in phage M13 (SeqWright, Houston, TX). The inserts in cosmids 8H3 and 9D3 overlapped, The inserts in cosmids 9D3 and 9F4 overlapped, and the insert in 9F4 and 10CI overlapped. See -21- WO 02/079477 PCT/US02/09968 -22 Fig. 2. Together, the four cosmid inserts spanned about 111 kb of unique sequence (SEQ ID NO: 1 & 2). SEQ ID NO 1 includes the start codon of busA and all DNA to the 3' of that (see Fig. 2.). SEQ ID NO. 2 begins the base before the busA start codon and includes all DNA to the 5' side of that base. The following Table 3 identifies the portions of SEQ ID NO:1 and SEQ ID NO. 2 included in each of the four inserts. Table 3 insert Inseit Size bases in SEQ bases in SEQ (base pairs) ID NO: 1 ID NO: 2 cosmid 8H3 40,364 1-3,826 1-36,538 cosmid 9D3 31,743 1-30,200 1-1,543 cosmid 9F4 36,935 17,437-54,372 none cosmid 1OC1 40,618 34,624-75,242 none FIG. 2 gives a graphical representation of the relationship of the four inserts to the 110kb of sequence. PKS Genes [0097] SEQ ID NO:1 includes a central region of about 60 kb with striking homology to the DNA encoding the polyketide synthases of known macrolide producers (Donadio et al., 1991; McDaniel & Katz., 2001; Deboff et al., 1997). The butenyl-spinosyn PKS DNA region consists of 5 ORFs with in-frame stop codons at the end of ACP domains, similar to the PKS ORFs in the other macrolide-producing bacteria. The five butenyl-spinosyn PKS genes are arranged head-to-tail (see FIG. 2), without any intervening non-PKS functions such as the insertion element found between the erythromycin PKS genes AI and AII (Donadio et al., 1993). The PKS genes are designated busA, busB, busC, busD, and busE. The nucleotide sequence for each of the five spinosyn PKS genes, and the corresponding polypeptides, are identified in the following Table 4: Table 4 GENE BASES IN SEQ [D NO:1 CORRESPONDING POLYPEPTIDE busA 1-13,032 SEQ ID NO: 3 busB 13,059-19,505 SEQ ID NO: 4 busC 19,553-29,053 SEQ ID NO: 5 busD 29,092-43,890 SEQ ID NO: 6 busE 43,945-60,636 SEQ ID NO: 7 [00981 busA encodes the initiator module (SEQ ID NO:1, bases 1-293 1), extender module b (SEQ ID NO:1, bases 2992-8130) and extender module 1 (SEQ II) NO:1, bases -22- WO 02/079477 PCT/US02/09968 -23 8205-13032). The nucleotide sequence and corresponding amino acid sequence for each of the functional domains within the iniliator module and extender modules b and 1 are identified in the following Table 5: Table 5 busA DOMAIN BASES IN SEQ ID NO:1 AMINO ACIDS IN SEQ ID NO:3 KSi 16-1269 6-423 ATi 1582-2559 528-853 ACPi 2683-2931 895-977 KSb 2992-4239 998-1413 ATh 4483-5508 1495-1836 DHb 5538-6084 1846-2028 KRb 6916-7554 2306-2518 ACPb 7861-8130 2621-2710 KS1 8203-9480 2735-3160 ATI 9721-10812 3241-3604 KR1 11719-12258 3907-4086 ACP1 12541-12786 4181-4262 [0099] busB encodes extender module 2 (SEQ ID NO:1, bases 13059-19505). The nucleotide sequence and corresponding amino acid sequence for each of the functional domains within extender module 2 are identified in the following Table 6: Table 6 busB DOMAIN BASES IN SEQ ID NO: 1 AMINO ACIDS IN SEQUENCE ID NO. 4 KS2 13059-14321 1-421 AT2 14658-15900 534-964 DH2 16026-16283 990-1075 ER2 17064-18101 1336-1681 KR2 18111-18650 1685-1864 ACP2 18915-19151 1953-2031 [00100] busC encodes extender module 3 (SEQ ID NO: 1, bases 19553-24061) and extender module 4 (SEQ ID NO:1, bases 24128-29053). The nucleotide sequence and corresponding amino acid sequence for each of the functional domains within extender modules 3 and 4 are identified in the following Table 7: Table 7 busC DOMAIN BASES IN SEQ ID NO:1 AMINO ACIDS IN SEQ ID NO:5 KS3 19553-20815 1-421 -23- WO 02/079477 PCT/US02/09968 -24 AT3 21134-22000 528-814 KR3 23021-23557 1157-1335 ACP3 23816-24061 1422-1503 KS4 24128-25399 1526-1949 AT4 25739-26731 2063-2393 KR4 27641-28183 2697-2877 ACP4 28457-28699 2969-3049 [00101] busD encodes extender module 5 (SEQ ID NO:1, bases 29092-34263), extender module 6 (SEQ ID NO:1, bases 34327-38892), and extender module 7 (SEQ ID NO:1, bases 38956-43503). The nucleotide sequence and corresponding amino acid sequence for each of the functional domains within extender modules 5, 6, and 7 is identified in the following Table 8: Table 8 busD DOMAIN BASES IN SEQ ID NO:1 AMINO ACIDS IN SEQ ID NO:6 KS5 29092-30357 1-422 AT5 30700-31683 537-864 DH5 31762-32319 891-1076 KR5 33235-33780 1382-1563 ACP5 34018-34263 1643-1724 KS6 34327-35601 1746-2170 AT6 35932-36924 2281-2611 KR6 37831-38370 2914-3093 ACP6 38647-38892 3186-3267 KS7 38956-40224 3289-3711 AT7 40560-41544 3823-4151 KR7 42115-42999 4342-4636 ACP7 43258-43503 4723-4804 [00102] spnE encodes extender module 8 (SEQ ID NO:1, bases 43945-49083), extender module 9 (SEQ ID NO:1, bases 49195-54366), and extender module 10 (SEQ ID NO:1, bases 54466-60707). The nucleotide sequence and corresponding amino acid sequence for each of the functional domains within extender modules 8, 9, and 10 is identified in the following Table 9: Table 9 busE DOMAIN BASES IN SEQ ID NO:1 AMINO ACIDS IN SEQ ID NO:7 KS8 43945-45216 1-424 AT8 45532-46488 530-848 DH8 46597-47160 885-1072 -24- WO 02/079477 PCT/US02/09968 -25 busE DOMAIN BASES IN SEQ ID NO:1 AMINO ACIDS IN SEQ ID NO:7 KR8 48055-48606 1371-1554 ACP8 48892-49083 1650-1728 KS9 49195-50469 1751-2175 AT9 50809-51792 2289-2616 DH9 51868-52269 2642-2775 KR9 53335-53889 3131-3315 ACP9 54130-54366 3396-3474 KS10 54466-55707 3508-3921 AT10 56050-57042 4036-4366 DH1O 57109-57651 4389-4569 KR1O 58570-59106 4876-5054 ACP10 59386-59631 5148-5229 TE10 59776-60537 5278-5531 [00103] The boundaries and functions of the 55 domains identified in the foregoing Tables 7-11 are predicted based on similarities to the conserved amino acid sequences of the domains in other polyketide synthases, particularly the erythromycin polyketide synthase (Donadio et al., 1992). Like the A83543 spinosyn PKS, the bus PKS has a KSQ domain at the amino terminus of the initiator module. This KSQ domain cannot function as a p ketosynthase because it contains a glutamine residue at amino acid 172, in place of the cysteine required for p-ketosynthase activity (Siggard-Andersen, 1993). It has been reported that KSQ domains function to decarboxylate malonyl-ACP and are chain initiation factors (Bisang, et al., 1999). The other butenyl-spinosyn PKS domains are functional. None of them has the sequence characteristics of the inactive domains found in the erythromycin and rapamycin PKS genes (Donadio et al., 1991; Aparicio et al., 1996). [00104] Although busB-E are comparable in size to spnB-E, busA is 5,244 bp larger than spnA. The first 4245 bp and the last 3,486 bp of busA have high similarity to spnA. However, bases 4246-9548 do not have counterparts in the spnA gene. This 5 kb region codes for an additional module with 5 functional domains: KSb, ATh, DHb, KRb, and ACPb. These functions together with the preceding initiation domain are responsible for the biosynthesis of the butenyl side chain, characteristic of butenyl-spinosyns relative to the A83543 spinosyns. The cloned bus PKS genes busB, busC, busD and busE were shown to be similar to the analogous A83543 spinosyn PKS genes spnB, spnC, spnD and spnE (table 10) (Baltz et al., 2000). -25- WO 02/079477 PCT/US02/09968 PAGE INTENTIONALLY LEFT BLANK WO 02/079477 PCT/USO2/09968 27 oo 0 S0 ''F JR - Cf ' ' C0 o 0 '4 00 -4 "0~0 ~'4 ' 00 00 tna) r- r tjn cn qr * 27 WO 02/079477 PCT/US02/09968 PAGE INTENTIONALLY LEFT BLANK WO 02/079477 PCT/US02/09968 -29 [001051 The proteins, which perform similar reactions in the biosynthesis of spinosyns, share 87-93 % amino acid identity and the genes range from 93-94 % DNA sequence identity. It should be noted that the spn PKS enzymes SpnB-E and the similar bus PKS enzymes BusB-E must maintain distinct substrate specificity since, although the reactions performed by the enzymes are identical, the substrate polyketides are different. In addition, aggregation of the 5 PKS enzymes into a functional PKS requires specific protein-protein interactions. The residues involved in. this inter-subunit molecular recognition are unknown and may not be conserved between S. spinosa and Saccharopolyspora sp. LWI07129 (NRRL 30141) Genes Adjacent to the PKS Responsible for Additional Modifications [00106] In the DNA upstream of the PKS genes (cloned in cosmid 8H3) there were 22 open reading frames (ORFs), each consisting of at least 100 codons, beginning with ATG or GTG and ending with TAA, TAG or TGA, and having the codon bias expected of protein coding regions in an organism whose DNA contains a high percentage of guanine and cytosine residues (Bibb et al., 1984). These 22 ORFs represented graphically in FIG. 2. Based on evidence that will be discussed hereinafter, 14 of the ORFs have been designated as butenyl-spinosyn biosynthetic genes, namely: busF, busG, busH, busl, busJ, busK, busL, busM, busN, busO, busP, busQ, busR, and busS (labeled F through S in FIG. 2). In the following Table 11, the DNA sequence and the amino acid sequence for the corresponding polypeptide are identified for each of these genes, as well as for ORFs found immediately downstream of spnS (ORF LI, ORF LII ORF LIII, ORF LIV, ORF LVI, ORF LVII, ORF LVIII and ORF LIX in cosmid 8H3). Also identified in Table 11 are the nucleotide sequences for ORF RI, ORF RII and ORFRIII downstream of the PKS genes (in cosmid 2C10), and the amino acid sequences corresponding to them. Table 11 Gene bases in Sequence ID NO: 2 polypeptide buSF 114-938 (C) SEQ ID NO: 8 busG 1389-2558 SEQ ID NO: 9 busH 2601-3350 SEQ ID NO: 10 busl 3362-4546 (C) SEQ ID NO: 11 busJ 4684-6300 SEQ ID NO: 12 busK 6317-7507 SEQ ID NO: 13 busL 7555-8403 SEQ ID NO: 14 busM 8640-9569 SEQ ID NO: 15 -29- WO 02/079477 PCT/US02/09968 -30 Gene bases in Sequence ID NO: 2 polypeptide busN 9671-10666 (C) SEQ ID NO: 16 busO 10678-12135 (C) SEQ ID NO: 17 busP 12867-14177 (C) SEQ ID NO: 18 busQ 14627-15967 SEQ ID NO: 19 busR 16008-17141 SEQ ID NO: 20 busS 17168-17914 SEQ ID NO: 21 ORF LI 18523-19932 (C) SEQ ID NO: 22 ORF LII 19982-20488 (C) SEQ ED NO: 23 ORF LIII 20539-21033(C) SEQ ID NO: 24 ORF LIV 21179-21922 SEQ ID NO: 25 ORF LVI 22674-23453 (C) SEQ ID NO: 26 ORF LVII 23690-24886 (C) SEQ ID NO: 27 ORF LVIII 26180-26923 (C) SEQ ID NO: 28 ORF LIX 27646-28473 SEQ ID NO; 29 Gene bases in Sequence ID NO:1 Polypeptide ORF RI 62090-63937 SEQ ID NO: 30 ORF RII 65229-66602 (C) SEQ ID NO: 31 ORF RIII 68762-69676 (C) SEQ ID NO: 32 (C) indicates complementary strand is given in the sequence listing [00107] To assign functions to the polypeptides identified in Table 11, four lines of evidence were utilized: similarity to sequences of known function, similarity to A83543 spinosyn biosynthetic genes, results of targeted gene disruption experiments, and results of bioconversion experiments. [00108] The amino acid sequences of the predicted polypeptides were compared to sequences deposited in the databases at the National Center for Biotechnology Information (NCBI, Washington, DC), using the BLAST algorithm to determine how well they are related to known proteins. The BLAST searches of the NCBI databases were also repeated periodically to obtain new insights from additional homologies. Table 12 gives significant matches from a basic BLAST search on February 18, 2001: Table 12 Gene Significant Protein Match GenBank BLAST Reported function Accession Score* busF C-5-0-methyltransferase aveD T44579 156 C-methylation (Streptonyces averinitilis) busG Glycosyl transferase urdGTlb AF164961 205 glycosyl transfer I (Streptomycesfradiae) busH 3"'macarocin 0-methyltransferase tylF AF147703 297 sugar methylation (Streptomycesfradiae) sugar ___ __ __ -30- WO 02/079477 PCT/US02/09968 -31 Gene Significant Protein Match GenBank BLAST Reported function Accession Score* busl 2"'macarocin 0-methyltransferase tylE AAD12164 287 sugar methylation (Streptomycesfradiae) busJ Hexose oxidase (Chondrus crispus) U89770 148 Hexose oxidase busK 2"'macarocin 0-methyltransferase tylE AAD12164 310 sugar methylation (Streptomycesfradiae) busL mitMmethyltransferase AF127374 120 C-methylation (Streptomyces lavenduale) busM Lip4 secretory lipase (Candida B70543 94 lipase albicans) busN 3-ketoreductase aknQ (Streptomyces AF264025 284 hexose 3 galilaeus) ketoreductase busO urdS (Streptomycesfradiae) AF269227 404 hexose 2,3 dehydration busP dnrH glycosyl transferase (Streptomyces U77891 290 glycosyl transfer puecetius) I busQ urdQ 3,4-dehydratase (Streptomyces AF269227 480 hexose fradiae) dehydratase busR spsC spore coat polysaccharide binding P39623 185 hexose protein (Bacillus subtillus) transamination busS desVIN,N-dimethyl transferase AF079762 240 . amino methylation (Streptomyces venezuelae) ORF LI ngt N-glycosyltransferase AB023593 221 glycosyltransfer (Saccharothrix aerocologenies) ORPLIV urdR hexose-4-ketoreductase AF080235 243 hexose (Streptomycesfradiae) ketoreduction ORFLVI fkbM, FK506 0-methyltransferase U65940 100 methyltransfer ORF LVII oleP, P450 monooxygenase L37200 387 monooxygenase (Streptomyces antibioticus) ORF LVII Transposase (Mycobacterium avium) AF107207 180 transposition OAF LIX mmciR (Streptomyces lavendulae) AF127374 124 Methyl transfer ORF RI resolvase-like protein (Acidithiobacillus U73041 97 transposition ferrooxidans) ORP RE hypothetical proteinyvmC(Bacillus AF017113 120 subtillus) ORF REI alcohol dehydrogenase [Streptomyces AL133236 155 alcohol coelicolor A3(2)] I dehydrogenase * Greater similarity is associated with higher BLAST scores (Altschul et al., 1990). [00109] The bus open reading frames were compared directly to the sequence of the A83543 spinosyn biosynthetic genes (Accession number AY007564). The high degree of similarity in both the DNA and protein sequence indicated that the genes performed similar functions in biosynthesis of spinosyns. Table 13 gives the similarity comparisons between the bus and spn genes -31- WO 02/079477 PCT/US02/09968 -32 Table 13 butenyl- bus ORF A83543 spn ORF BLAS ORF ORF Function spinosyn length spinosyn length T % % reported in Gene bp (a.a.) gene bp (a.a.) score Identit Identit GenBank y y (aa.) (DNA) busF 828 (275) spnF 828 1247 94 % 91 % C-methylation (275) busG 1173 spnG 1173 1844 95% 90% sugar addition (390) (390) busH 753(250) spnH 754 1328 97% 97% sugar (250) methylation busl 1188 spnl 1188 1966 96% 92% unknown (395) (395) busJ 1620 spnJ 1620 2587 95 % 83 % oxido-reduction (539) (539) busK 1194 spnK 1194 2163 96% 88% unknown (397) (397) busL 852 (283) spnL 852 2274 94 % 94 % C-methylation (283) busM 933(310) spnM 963 1909 95% 96% unknown (320) busN 999 (332) spnN 999 1772 96 % 91 % unknown (332) busO 1461 spnO 1461 2319 95% 92% deoxysugar (486) (486) synthesis busP 1314 spnP 1368 2004 94% 89% sugar addition (437) (455) _ busQ 1344 spnQ 1389 2355 94 % 81 % dideoxysugar (447) (462) synthesis busR 1137 spnR 1158 1852 95% 89% sugar (378) (385) 1anamination busS 750 (249) spnS 750 1255 96 % 93 % aminosugar (249) methylation [00110] In spite of the high degree of DNA and amino acid similarity between some bus & spn genes, it should be noted that some of the bus gene products catalyze markedly different reactions in the biosynthesis of butenyl-spinosyn relative to A83543 spinosyns. These differences are manifested in the distinct butenyl-spinosyn compounds that have been isolated from Saccharopolyspora sp. LW107129 (NRRL 30141). All natural A83543 spinosyns disclosed are substituted at C-17 with forosamine or a specific forosamine isomer (Kirst, et al., 1992). Butenyl-spinosyns, on the other hand, are also substituted at C-17 with a wider range of forosamine isomers, as well as neutral sugars like amicetose, 0-methyl -32- WO 02/079477 PCT/US02/09968 -33 glucose and O-methyloleandrose. This C-17 glycosylation diversity relative to A83543 spinosyns requires biosynthetic enzymes to make the sugars and a glycosyltransferase capable of catalyzing these glycosylations. These sugars might be synthesized by specific synthase genes located near the bus genes or elsewhere in the chromosome, or they may be synthesized by alternate substrate specificity of the listed butenyl-spinosyn biosynthetic genes. Amicetose could be produced by genes outside of the bus gene cluster or it may be an intermediate in the biosynthesis of forosamine (FIG. 4). Methyloleandrose could be produced as a byproduct of forosamine biosynthesis and the rhamnose 0-methyltransferases (busH, busI & busK). This sugar could be synthesized from NDP-4-keto-2,6-deoxy-D glucose is an intermediate in the biosynthesis of forosamine. Therefore, ketoreduction and 0-methylation of this precursor by the disclosed genes and other Saccharopolyspora sp. LW107129 (NRRL 30141) genes could lead to the biosynthesis of spinosyn derivatives containing methyloleandrose (FIG. 4). [00111] In addition, nine genes listed in table 13 directly interact with the butenyl spinosyn aglycone or PSA (busF, busG, busH, busI, busJ, busK, busL, busM, and busP). The aglycone and PSA substrate for these genes is distinct from the A83543 spinosyn aglycone and PSA. Therefore, these genes have distinct substrate specificity relative to their spn counterpart listed in Table 13. [00112] Several butenyl-spinosyn analogs produced by Saccharopolyspora sp. LW107129 (NRRL 30141) are hydroxylated at C-8 or C-24 (Table 2). Macrolides can be hydroxylated post synthesis by P-450 monooxygenases as in hydroxylation at C-6 in erythromycin biosynthesis (Weber & McAlpine, 1992). ORF LVII is highly similar to P 450 monooxygenases and it or a monooxygenase encoded elsewhere on the Saccharopolyspora sp. LW107129 (NRRL 30141) chromosome may be responsible for the hydroxylations at C-8 or C-24 of butenyl-spinosyns. Alternatively, hydroxylated precursors such as glycolate or glycerol can be incorporated during polyketide synthesis as in leucomycin (Omura et al., 1983). It has been reported that the AT domain specific for addition of glycolate in the niddamycin producer (nid AT6) is similar to methyl-malonyl CoA specific AT domains of the erythromycin and rapamycin PKS genes (Katz et al., 2000). PKS module 7 is responsible for addition of carbons 8 and 9 of the butenyl-spinosyn polyketide, however, the bus AT7 domain does not have the same methyl-malonyl-CoA -33- WO 02/079477 PCT/US02/09968 -34 specific sequences as nid AT6. There are unique sequences in bus AT7 relative to other AT domains and nid AT6 which could be responsible for glycolate specificity. The butenyl spinosyn biosynthetic genes responsible for these modifications are unique relative to the A83543 spinosyns since no such hydroxylated spinosyns are produced by S. spinosa. [001131 In addition, the specificity of rhamnose methylation is altered in Saccharopolyspora sp. LW107129 (NRRL 30141) relative to S. spinosa. Mutants of S. spinosa which exhibited altered methylation of the rhamnose on A83543 spinosyn as disclosed in US Patents 5,202,242 and 5,840,861, typically produced mono-desmethylated rhamnose derivatives of A83543 spinosyns. Di-desmethyl rhamnose derivatives of A83543 spinosyns were only detected in the presence of methyltransferase inhibitors like sinefungin. Mutants of Saccharopolyspora sp. LW1 07129 (NRRL 30141) with altered methylation of rhamnose (Hahn et al., 2001), produced di- and tri-desmethyl rhamnose derivatives of butenyl-spinosyns in high amounts, in the absence of methyltransferase inhibitors. [001141 For complementation studies, cosmids containing Saccharopolyspora sp. LW107129 (NRRL 30141) bus DNA were conjugated into Saccharopolyspora sp. LW107129 (NRRL 30141) mutant strains in which butenyl-spinosyn synthesis was altered. (Details are given in the following Example 4.) Transconjugants were then tested for their ability to convert the products of blocked mutants into other spinosyns. The mutant used was 30141.8 which produced 3'-O-desmethylrhamnose-butenyl-spinosyn (3 ODM) and related factors. The 30141.8/8H3 transconjugants produced butenyl-spinosyns instead of 3-ODM, so the genes responsible for methylation at the 3' position of rhamnose must be present on cosmid 8H3. [00115] In targeted gene disruptions, internal fragments are generated by PCR amplification from the cosmid DNAs, and cloned into a plasmid. The resulting plasmids were then conjugated into Saccharopolyspora sp. LW107129 (NRRL 30141, and apramycin-resistant transconjugants were isolated and fermented. The basis of disruption experiments is that when a plasmid bearing an internal gene fragment is integrated, two incomplete copies of the biosynthetic gene result, thereby eliminating the enzymatic function. Fermentation products are analyzed to determine which butenyl-spinosyns accumulate. Disruption of the busO gene leads to the accumulation of butenyl-spinosyn PSA indicating that busO is required for synthesis or addition of forosamine (See Example -34- WO 02/079477 PCT/US02/09968 -35 5). Compounds containing sugars at C-17 which are not synthesized using the forosamine biosynthetic genes can also be accumulated in busO mutants. [001161 The conclusions drawn from BLAST searches, the gene disruption experiments, and the bioconversion studies will now be discussed in greater detail on a gene by gene basis. [00117] The 14 genes upstream of the PKS were determined to be involved in butenyl spinosyn biosynthesis because of their high similarity to the spnF-S genes of S. spinosa (Table 13) and because BLAST searches showed that these genes had striking similarity to enzymes known to code for functions needed for the biosynthesis of butenyl-spinosyns. busF. busJ, busL, busM [00118] The genes busF, busJ, busL, and busM show high similarity to spnF, spnJ, spnL and spnM. These A83543 spinosyn genes were reported to be involved in generation of the aglycone from the putative monocyclic lactone product of the PKS genes. The busF gene product has 91 % amino acid identity to spnF, likewise the busL gene product has 94 % amino acid identity to spnL. Both spnF & spnL gene products were reported to be methyltransferases and all 4 proteins have high similarity to enzymes from Streptomyces which are known to be involved in carbon-carbon bond formation, The busJprotein had 83 % amino acid identity to spnJ, reported to be an oxidoreductase. Both busJ & spnJ are highly similar to dnrW, which is known to be involved in C-C bond formation in the biosynthesis of daunorubicin. The busM gene product was 96 % identical to spnM. The gene products of both busM & spnM are highly similar to a new class of secreted lipases from Candida albicans. The roles of busF, and busL as methyltransferases, busJas an oxidase and busM as a lipase are consistent with the reported roles of the spnF, spnL, spnJ and spnM genes in the formation of carbon-carbon bridges. busG. busH. busl, busK [00119] The busG, busH, busl, and busK had high similarity to the spnG, spnH, spnl and spnK genes of S. spinosa. These genes were reported to be involved in rhamnose addition to the A83543 spinosyn aglycone and subsequent methylation. The busG gene has 90% similarity to spnG and was highly similar to several genes involved in sugar addition to polyketide derived antibiotics (table 11). The busH, busl, and busK gene products showed high amino acid similarity to the spnH (97 %), spnI (92 %), and spnK (88 %) gene products, -35- WO 02/079477 PCT/US02/09968 -36 respectively which were reported to be involved in methylation of rhamnose in spinosyn biosynthesis. All three genes had high amino acid similarity to the tylE (busl& busK) and tylF (busH) genes from Streptomycesfradiae which have been shown experimentally to be macarocin-O-methyltransferases (Bate & Cundliffe, 1999). busN, busO, busP, busO, busR. busS [00120] The spnN, spnO, busP, busQ, busR, and busS had high similarity to the spnN, spnO, spnP, spnQ, spnR, and spnS genes of S. spinosa (Table 12). These genes were reported to be involved in the biosynthesis or addition of the forosamine sugar. The similarity of busP to other glycosyl transferases (Table 11) indicates that it encodes the butenyl-spinosyn forosamyl transferase. The high degree of similarity between busO and the urdS 2,3 dehydratase (Table 11; Hoffmeister et al., 2000) indicates that it is involved in the 2'-deoxygenation step of forosamine synthesis. The similarity between the busQ gene product and the urdQ 3,4-dehydratase (S. fradiae; Hoffmeister et al., 2000), indicates that it is involved in the 3'-dehydration step of forosamine synthesis. busR had up to 40% identity to a group of proteins proposed to function as deoxysugar transaminases (Thorson et al., 1993), indicating that busR is involved in the 4'-amination step of forosamine synthesis. Finally busS was highly similar to a group of amino methylases indicating that busS is involved in methylation of the 4' amino group of forosamine. Therefore, the busN, busO, busP, busQ, busR, and busS are involved in production of the forosamine moiety of butenyl spinosyns. [00121] Thus 19 genes from Saccharopolyspora sp. LW107129 (NRRL 30141) can be assigned roles in butenyl-spinosyn biosynthesis: 5 PKS genes to produce a macrocyclic lactone, 4 genes to modify this to the aglycone, 4 genes to add and methylate the rhamnose, and 6 genes to synthesize and add forosamine. The hypothetical biosynthetic pathway is summarized in FIGS. 1A'and 1B. [00122] There are many uses for the cloned Saccharopolyspora sp. butenyl-spinosyn DNA. The cloned genes can be used to improve yields of butenyl-spinosyns and to produce new butenyl-spinosyns. Improved yields can be obtained by integrating into the genome of a particular butenyl-spinosyn producing strain, a duplicate copy of one or more butenyl spinosyn biosynthetic genes. In the extreme case where the biosynthetic pathway is blocked -36- WO 02/079477 PCT/US02/09968 -37 in a particular mutant strain due to lack of a required enzyme, production of the desired spinosyns can be restored by integrating a copy of the required gene. [00123] Novel compounds can be produced using fragments of the cloned DNA to disrupt steps in the biosynthesis of butenyl-spinosyns. Such disruption may lead to the accumulation of precursors or "shunt" products (the naturally-processed derivatives of precursors). Modified spinosyns produced by disrupting genes may be insect control agents themselves, or serve as substrates for further chemical modification, creating new semi synthetic spinosyns with unique properties and spectra of activity. A disruption of the busO gene results in the accumulation of butenyl-spinosyn PSA. Butenyl-spinosyn PSA is useful as a starting material for the synthesis of spinosyn analogs containing novel groups at C-17. [00124] Novel butenyl-spinosyns can also be produced by transfer of one or more of the cloned bus genes, or a part thereof, into a heterologous host. These genes may provide enzymatic functions not present in the recipient host. Such genes might provide alternate sugars, modify existing sugars or aglycone carbons, allow alternate sugars to be attached to an aglycone or alter the base structure of the aglycone itself. Compounds produced by transfer of the cloned bus genes into a heterologous host may be insect control agents themselves, or serve as substrates for further chemical modification, creating new semi synthetic spinosyns with unique properties and spectra of activity. Saccharopolyspora sp. LW107129 (NRRL 30141) DNA from cosmids 8H3 and 9D3 can be transferred into S. spinosa, producer of A83543 spinosyns, and the transconjugants produce novel spinosyns. [00125] Novel butenyl-spinosyns can also be produced by mutagenesis of the cloned genes, and substitution of the mutated genes for their unmutated counterparts in a butenyl spinosyn-producing organism. Mutagenesis may involve, for example: 1) deletion or inactivation of a KR, DH or ER domain so that one or more of these functions is blocked and the strain produces a spinosyn having a lactone nucleus with a double bond, a hydroxyl group, or a keto group that is not present in the nucleus of spinosyn A (see Donadio et al., 1993); 2) replacement of an AT domain so that a different carboxylic acid is incorporated in the lactone nucleus (see Ruan et al., 1997); 3) addition of a KR, DH, or ER domain to an existing PKS module so that the strain produces a spinosyn having a lactone nucleus with a saturated bond, hydroxyl group, or double bond that is not present in the nucleus of spinosyn A (MacDaniel & Katz, 2001); or 4) addition or subtraction of a complete PKS -37- WO 02/079477 PCT/US02/09968 -38 module so that the cyclic lactone nucleus has a greater or lesser number of carbon atoms. [00126] The DNA from the butenyl-spinosyn gene cluster region can be used as a hybridization probe to identify homologous sequences. Thus, the DNA cloned here could be used to locate additional plasmids from the Saccharopolyspora sp. LW107129 (NRRL 30141) gene libraries which overlap the region described here but also contain previously uncloned DNA from adjacent regions in the genome of Saccharopolyspora sp. LW107129 (NRRL 30141). Also, comparisons of the Saccharopolyspora sp. LW107129 (NRRL 30141 bus genes with the S. spinosa spn genes leads to the identification of regions of conserved sequence which are distinct from non-spinosyn producing biosynthetic genes such as the biosynthetic genes for erythromycin, rapamycin, tylosin and others. These spinosyn-specific gene probes as well as all DNA from the region cloned here may be used to identify non-identical but similar sequences in other organisms. Hybridization probes are normally at least about 20 bases long and are labeled to permit detection. [00127] The modified strains provided by the invention may be cultivated to provide spinosyns using conventional protocols such as those disclosed in U. S. Patent No. 5,362,634 or provisional U. S. Patent Application 60/277,601 on "Pesticidal Macrolides", filed March 21,2001. The above examples are non-limiting and should not be construed as limitations of the invention. EXAMPLE 2 LC/MS Method for Analysis of Fermentation Broth for Butenyl-Spinosyn Metabolites [00128] The following method utilizes HPLCseparation with electrospray (ESI) mass spectrometry to monitor fermentation for the production of Formula (1) and other components. Such a system was also used for determining molecular weights of the purified factors, by deduction from the electrospray adduct ions. These data are summarized in Table 15. [00129] Add a volume of denatured ethanol equal to that of fermentation broth. Shake the mixture for 1 hour, then centrifuge and filtere (0.22 pm pore size) to remove the bulk cell debris. Microfuge a 1-mL aliquot, then analyze the clarified extract by the following LC-MS system: [00130] HPLC system: Column stationary phase: 250 x 4.6-mm column, base deactiviated silica gel, 5 pm C8 (Hypersil-C8-BDS). Mobile phase: 10 mM ammonium -38- WO 02/079477 PCT/US02/09968 -39 acetate-methanol-acetonitrile linear gradient summarized below: TABLE 14 Time (mins) Percent solvent A Percent solvent B 0 100 0 20 0 100 25 0 100 30 100 0 35 100 0 where solvent A is 10 mM ammonium acetate and solvent B is methanol acetonitrile (1:1); Flow rate: 1 mL/min; split after UV detector such that MS:waste ratio is approx. 5:95; Detection: positive ESI acquired in low and high cone voltage modes Characteristic LC retention times and mass spectrometry ions as summarized in Table 15. TABLE 15 Compound No. LC retention time m/z for [M+H]+ m/z for secondary (from Table 1) ion 1 23.8 758.4 142.0 (forosamine) 4 '- 22.9 744.4 142.0 5 24.3 772.4 142.0 6 22.1 774.4 142.0 9 21.4 810.4 [M+NH 4 ] 189.0 (tri-0 methyl-rhamnose) 13 22.0 617.3 189.0 a m/z for parent ion observed under +ESI mode, low cone voltage b m/z for most abundant fragment or adduct ion observed under +ESI, high cone voltage mode EXAMPLE 3 Preparation Of Butenyl-Spinosyn Metabolites Through Fermentation [001311 Metabolites of Formula (1) are produced by cultivation of the desired strain of Saccharopolyspora chosen from one of the following strains NRRL 30141, NRRL 30421, or derivatives thereof in fermentation medium as described below. A 1.8-mL frozen vegetative culture was thawed, inoculated into 25 mL vegetative media in a 125-mL Erlenmeyer baffled flask and grown at 300 C shaking at 150 rpm for 72-96 hours. TABLE 16 Vegetative Medium Ingredient Amount (g) Dextrose 9.0 -39- WO 02/079477 PCT/US02/09968 -40 Trypticase Soy Broth 30.0 Yeast Extract 3.0 Magnesium Sulfate. 7 H 2 0 2.0 De-ionized water 1000.0 Shake Flask Fermentation [00132] Twelve milliliters of mature first stage seed was used to inoculate 50-mL fermentation medium in a 500-mL baffled Erlenmeyer fermentation flask. TABLE 17 Fermentation Medium (per liter of water) Ingredient Amount (g) Dextrose 80.0 Cottonseed Flour 32.0 Soybean Flour 8.0 Corn Steep Powder 8.0 Calcium Carbonate 5.0 Yeast Extract 2.0 [00133] Fermentation was maintained at 300 C, 200 rpm (50 mm stroke) for 7-12 days. Mature fermentation beer can be extracted with a suitable solvent and the metabolites recovered by chromatographic separation, as disclosed in Example 1. EXAMPLE 4 Complementation of Rhamnose Methylation Defect in Strain NRRL 30421 by Cosmid 8H3 [00134] Strain NRRL 30421 is a mutant of Saccharopolyspora sp. NRRL 30141 which is unable to fully methylate the rhamnose on butenyl-spinosyns. Strain NRRL 30421 accumulates compound 4 and other butenyl-spinosyns which lack O-methylation at the 3' position of the rhamnose (3'-ODM). This methylation defect is presumed to be the result of a mutation in one of the O-methyltransferases encoded by the busH, busl or busK genes. All of these genes are present in cosmid 8H3 (Figure 2) [00135] Cosmid 8H3 (Figure 3) was transferred from Escherichia coli ATCC 47055 into strain NRRL 30421 by conjugal transfer (Matsushima et al., (1994)). Two independent isolates transformed with cosmid 8H3 were fermented as in Example 2 and analyzed for production of compound 1 and compound 4 as exemplified in Example 1. TABLE 18 Strain (Genotype) compound 4 compound 1 ratio of pg/ml pg/ml compounds 1:4 NRRL 30421 (3'-ODM*) 1.0 0.7 0.7 NRRL 30421 (3'- 0.5 8.9 17.8 -40- WO 02/079477 PCT/US02/09968 -41 ODM*)/8H3-42 NRRL 30421 (3'- 0.1 3.0 30.0 ODM*)/8H3-45 NRRL 30141 0.4 9.7 24.3 *= mutation preventing methylation of rhamnose at 3' position [001361 While NRRL 30421 produced predominantly compound 4, strains of NRRL 30421 containing cosmid 8H3 produced mostly compound 1 [Table 18]. The production of compounds 1 and 4 in NRRL 30421 containing cosmid 8H3 is similar to the non-mutant culture NRRL 30141 (Table 18). It has therefore been demonstrated that transformation with cosmid 8H3 is able to overcome a methylation defect in strain NRRL 30421 to restore enhanced production of compound 1. EXAMPLE 5 Accumulationation of Butenyl-Spinosvn Precursor and Shunt Product Caused by Disruption ofbusO [001371 The busO gene was inactivated by integration of a cloned internal fragment of the busO gene. A pair of oligonucleotides (the first corresponding to bases 11882-11861 in SEQ ID NO: 2 and the second corresponding to bases 10970-10993 in SEQ ID NO: 2) were used to amplify a 912 bp region internal to the 1,457 bp busO gene corresponding to bases 10970-11882 in SEQ ID NO: 2. Transformation of Saccharopolyspora sp. LW107129 (NRRL 30141) with aplasmid containing the fragment would result in partial duplication of the busO gene, to yield two truncated copies of the gene flanking the plasmid and antibiotic resistance gene. [00138] The 912 bp internal busO PCR fragment was generated with primers SEQ ID NO: 33 & 34 using FailSafeTMPCR (Epicenter) and cloned into pCRII according to the manufacturer's instructions (Invitrogen). The resulting plasmid was digested with EcoRI and the busO fragment was cloned into the EcoRI site of pOJ260 (Figure 3). The resultant plasmid was conjugated from Escherichia coli ATCC 47055 into a derivative of Saccharopolyspora sp. NRRL 30121 by conjugal transfer (Matsushima et al., (1994)). Six independent apramycin resistant exconjugants were fermented as in Example 2 and analyzed for production of compound 1 and other spinosyn derivatives as in Example 1. [00139] The parental strain, NRRL 30141 produced high levels of compound 1 and low levels of the pseudoaglycone (PSA; compound 13). It also produced a small amount of compound 9 [Table 19]. Compound 1 could not be detected in any of the six busO mutants, -41- WO 02/079477 PCTIUS02/09968 -42 indicating that busO is required for complete butenyl spinosyn biosynthesis. In addition, levels of PSA were increased in all six busO mutants, as would be predicted from a deficiency in forosamine supply. The levels of compound 9 which has a sugar other than forosamine at C17, also increased in the busO mutants. TABLE 19 Strain (Genotype) compound 1* compound 13 compound 9 NRRL 30141 366.3 1.0 0.4 NRRL 30141 nd 13.8 1.7 busO65 NRRL 30141 nd 12.3 3.7 busO67 NRRL 30141 nd 6.7 3.8 busO68 NRRL 30141 nd 9.3 1.3 busO7O NRRL 30141 nd 12.3 2.4 busO71 NRRL 30141 nd 5.4 1.6 busO72 * amounts reported are relative to compound 13 in NRRL 30141; nd =not detected -42- WO 02/079477 PCT/US02/09968 -43 References 1. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman (1990). Basic local alignment search tool. J. Molec. Biol. 215:403-10. 2. Aparicio, J. F., I. Molnar, T. Schwecke, A. Konig, S. F. Haydock, L. E. Khaw, J. Staunton & J. F. Leadlay (1996). "Organization of the biosynthetic gene cluster for rapamycin in Streptomyces hygroscopicus: analysis of the enzymatic domains in the modular polyketide synthase," Gene 169: 9-16. 3. Ausebel F., R. Brent, R. Kingston, D. Moore, J. Smith, J. Seidman, and K. Struhl, eds. (1987). Current Protocols in Molecular Biology. (John Wiley and Sons, New York). 4. Baltz, R. H., M. C. Broughton, K. P. Crawford, K. Madduri, D. J. Merlo, P. J. Treadway, J. R. Turner and C. Waldron (2000) Biosynthetic Genes for Spinosyn Insecticide Production. US Patent 6,143,526. 5. Bate, N., & E. Cundeliffe (1999) The mycinose-biosynthetic genes of Streptomyces fradiae, J. Ind. Microbiol. Biotechnol. 23:118-122. 6. Bibb, M. J., P. R. Findlay & M. W. Johnson (1984). "The relationship between base composition and codon usage in bacterial genes and its use for the simple and reliable identification of protein-coding sequences," Gene 30: 157-166. 7. Bierman, M., R. Logan, K. O'Brien, E. T. Seno, R. N. Rao & B. E. Schoner (1992). "Plasmid cloning vectors for the conjugal transfer of DNA from Escherichia coli to Streptomyces spp," Gene 116: 43-49. 8. Broughton, M. C., M. L. B. Huber, L. C. Creemer, H. A. Kirst & J. A. Turner (1991). "Biosynthesis of the macrolide insecticidal compound A83543 by Saccharopolyspora spinosa," Ann. Mtg. Amer. Soc. Microbiol. 9. Bsang, C., P. F. Long, J. Cortes, J. Westcott, J. Crosby, A.-L. Matharu, R. J. Cox, T. J. Simpson, J. Staunton and P. F. Leadlay (1999) "A chain initiation factor common to both modular and aromatic polyketide synthases." Nature 401:502-505. 10. Burgett, S. G. and P. R J. Rosteck (1994) "Use of dimethyl sulfoxide to improve fluorescent, Taq cycle sequencing." in: Automated DNA Sequencing and Analysis. M. Adams, C. Fields and J. C. Venter, eds. NY, Academic Press: pp. 211-215. -43- WO 02/079477 PCTIUS02/09968 -44 11. Dehoff, B.S., S.A. Kuhstoss, P.R. Rosteck & K.L. Sutton (1997). "Polyketide synthase genes." EPA 0791655. 12. Donadio, S., J. B. McAlpine, P. S. Sheldon, M. Jackson & L. Katz (1993). "An erythromycin analog produced by reprogramming of polyketide synthesis," Proc. Nat!. Acad. Sci. USA 90: 7119-7123. 13. Donadio, S. & L. Katz (1992). "Organization of the enzymatic domains in the multifunctional polyketide synthase involved in erythromycin formation in Saccharopolyspora erythrae," Gene 111: 51-60. 14. Donadio, S., M. J. Staver, J. B. McAlpine, S. J. Swanson & L. Katz (1991). "Modular organization of genes required for complex polyketide biosynthesis," Science 252: 675 679. 15. Hoffmeister, D., K. Ichinose, S.:Dormann, B. Foust, A. Trefzer, G. Drager, A. Kirschining, C. Fischer, E. Kunzel, D. W. Bearden, J. Rhor and A. Bechthold (2000) The NDP-sugar co-substrate concentration and the enzyme expression level influence the substrate specificity of glycosyltransferases: cloning and characterization of the deoxysugar biosynthesis genes of the urdamycin biosynthetic gene cluster. Chemistry & Biology 7:821-831. 16. Ikeda, H., T. Nomoniya, M. Usami, T. Ohta and S. Omura (1999) Organization of the biosynthetic gene cluster of the polyketide anthelmintic macrolide avermectin in Streptomyces avermitilis. Proc. Nat. Acad. Sci. USA 96:9509-9514. 17. Jiang, X. M., B. Neal, F. Santiago, S. J. Lee, L. K. Romana & P. R. Reeves (1991). "Structure and sequence of the rfb (0 antigen) gene cluster of Salmonella serovar typhimurium (strain LT2)," Mot. Microbiol. 5: 695-713. 18. Katz, L., D. L. Stassi, R. G. Summers, Jr., X. Ruan, A. Pereda-Lopez and S. J. Kakavs. (2000) Polyketide derivatives and recombinant methods for making same. US Patent 6,060,234. 19. Kirst, H. A., K. H. Michel, J. W. Martin, L. C. Creemer, E. H. Chino, R. C. Yao, W. M. Nakatsukasa, L. D. Boeck, J. L. Occolowitz, J. W. Paschal, J. B. Deeter, N. D. Jones -44- WO 02/079477 PCT/US02/09968 -45 and G. D. Thompson. (1991) A83543A-D, unique fermentation-derived tetracyclic macrolides. Tetrahedron Lett. 32:4839-4842. 20. Liu, H.W. & J.S. Thorson (1994). "Pathways and mechanisms in the biogenesis of novel deoxysugars by bacteria," Ann Rev Microbiol 48: 223-256. 21. Matsushima, P., M. C. Broughton, J. R. Turner & R. H. Baltz (1994). "Conjugal transfer of cosmid DNA from Escherichia coli to Saccharopolyspora spinosa: effects of chromosomal insertion on macrolide A83543 production," Gene 146: 39-45. 22. McDaniel, R. & L. Katz (2001) Genetic engineering of novel macrolide antibiotics. In: Dev. Novel Antimicrob. Agents: Emerging Strategies; K. Lohner, Ed.; pp. 45-60; Horizon Scientific Press, Wymondham, UK. 23. Merson-Davies, L. A. and E. Cundeliffe (1994) Analysis of five tylosin biosynthetic genes from the tylIBA region of the Streptomycesfradiae genome. Mol Microbiol. 13:349-355. 24. Omura, S., K. Tsuzuki, A. Nakagawa, and G. Lukacs (1983) Biosynthetic origin of carbons 3 and 4 of leucomycin aglycone. J. Antibiot. 36:611-613. 25. Ruan, X., A. A Pereda, D. L. Stassi, D. Zeidner, R. G. Summers, M. Jackson, A. Shivakumar, S. Kakavas, M. J. Stavier, S. Donadio and L. Katz (1997). "Acyltransferase Domain Substitutions in Erythromycin Polyketide Synthase Yield Novel Erythromycin Derivatives," J Bacteriology 179, 6416-6425. 26. Sambrook, J. E. F. Fritch, and T. Maniatis (1989) Molecular Cloning a Laboratory Manual, Second Edition. (Cold Spring Harbor Press, Cold Spring Harbor, NY) 27. Schwecke, T., J. F. Aparicio, I. Molnar, A. Konig, L. E. Khaw, S. F. Haydock, M. Oliynyk, P. Caffrey, J. Cortes, J. B. Lester, G. A. Bohm, J. Staunton and P. F. Leadlay (1995) The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin. Proc. Nat. Acad. Sci. USA 92:7839-7843. 28. Shen, B., W. Liu, S. D. Christianson and S. Standage (2000) Gene cluster of the production of the enediyne antitumor antibiotic C-1027. WO App. 00/40596 29. Siggard-Andersen, M. (1993). "Conserved residues in condensing enzyme domains of -45- WO 02/079477 PCT/US02/09968 -46 fatty acid synthases and related sequences," Protein Seq. Data Anal. 5: 325-335. 30. Simon, R., U. Preifer & A. Puhler (1983). "A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in Gram negative bacteria," BiolTechnology 1: 784-791. 31. Strobel, R. J. & W. M. Nakatsukasa (1993). "Response surface methods for optimizing Saccharopolyspora spinosa, a novel macrolide producer," J. Ind. MicrobioL 11: 121 127. 32. Thorson, J. S., S. F. Lo & H. Liu (1993). "Biosynthesis of 3,6-dideoxyhexoses: new mechanistic reflections upon 2,6.-dideoxy, 4,6-dideoxy, and amino sugar construction," J. Am. Chem. Soc. 115: 6993-6994. 33. Trefzer, A., J. A. Salas and A. Bechthold (1999) Genes and enzymes involved in deoxysugar biosynthesis. Nat. Prod. Rep. 16:283-299. 34. Weber, J. M. & J. B. McAlpine (1992). "Erythromycin derivatives," U.S. Patent 5,141,926. 35. Wohlert, S.-B., N. Lomovskaya, K. Kulowski, L. Fonstein, J. L. Occi, K. M. Gerwain, D. J. MacNeil and C. R. Hutchinson (2000) Biosynthesis of the avermectin deoxysugar L-oleandrose and novel avermectins. Genetics and Molecular Biology of Industrial Microorganisms Conference, Bloomington, IN, USA. -46-

Claims (8)

1. An isolated DNA molecule comprising a DNA sequence that encodes a butenyl spinosyn biosynthetic enzyme, wherein said enzyme is comprised of an amino acid sequence at least 98% identical to SEQ ID NO 3, provided that if the sequence is less than 100% identical to the selected sequence, then the differences do not substantially effect the functional properties of the encoded enzyme.

2. An isolated DNA molecule of claim I wherein the DNA sequence is the busA gene, said gene being described by bases 1-13032 of SEQ ID NO:1.

3. A recombinant DNA vector which comprises a DNA sequence of claim 1 or claim 2.

4. A host cell transformed with a recombinant vector of claim 3.

5. A method of increasing the spinosyn-producing ability of a spinosyn-producing microorganism comprising the steps of 1) transforming with a recombinant DNA vector or portion thereof a microorganism that produces butenyl-spinosyn or a butenyl-spinosyn precursor by means of a biosynthetic pathway, said vector or portion thereof comprising a DNA sequence of the invention according to claim 1 or claim 2 that codes for the expression of an activity that is rate limiting in said pathway, and 2) culturing said microorganism transformed with said vector under conditions suitable for cell growth and division, expression of said DNA sequence, and production of spinosyn.

6. A process for preparing a butenyl-spinosyn which comprises cultivating a microorganism having operative butenyl-spinosyn biosynthetic genes in its genome, provided that the genome of the organism has been modified so that duplicate copies of the butenyl spinosyn biosynthetic gene busA is present.

7. Butenyl-spinosyn when produced by a process according claim 6.

8. A DNA molecule according to claim I or claim 2, substantially as herein described with reference to any one of the Examples.